Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Peter Moore

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Hospital Medicine (London, England : 1998)|September 10, 2003
Movement, visceral and autonomic disorders: use of botulinum toxinA Peter Moore
Movement Disorders : Official Journal of the Movement Disorder Society|September 23, 2003
Long-term safety of botulinum toxin type AMarkus Naumann, A Peter Moore
Clinical Evidence|September 17, 2002
Parkinson's diseaseCarl Clarke, A Peter Moore
Clinical Evidence|September 2, 2005
Parkinson's diseaseCarl Clarke, A Peter Moore
Clinical Evidence|November 24, 2004
Parkinson's diseaseCarl Clarke, A Peter Moore
Clinical Evidence|January 18, 2005
Parkinson's diseaseCarl Clarke, A Peter Moore
American Family Physician|April 13, 2007
Parkinson's diseaseCarl E Clarke, A Peter Moore
BMJ Clinical Evidence|May 21, 2009
Parkinson's diseaseCarl E Clarke, A Peter Moore
Neurology|April 14, 2004
Botulinum toxin A improves involuntary limb movements in Rasmussen syndromeDora A Lozsadi, Ian K Hart, A Peter Moore
Movement Disorders : Official Journal of the Movement Disorder Society|February 9, 2002
Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystoniaSusan H Fox, Mark Kellett, A Peter Moore, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Hospital Medicine (London, England : 1998)|September 10, 2003
Movement, visceral and autonomic disorders: use of botulinum toxinA Peter Moore
Movement Disorders : Official Journal of the Movement Disorder Society|September 23, 2003
Long-term safety of botulinum toxin type AMarkus Naumann, A Peter Moore
Clinical Evidence|September 17, 2002
Parkinson's diseaseCarl Clarke, A Peter Moore
Clinical Evidence|September 2, 2005
Parkinson's diseaseCarl Clarke, A Peter Moore
Clinical Evidence|November 24, 2004
Parkinson's diseaseCarl Clarke, A Peter Moore
Clinical Evidence|January 18, 2005
Parkinson's diseaseCarl Clarke, A Peter Moore
American Family Physician|April 13, 2007
Parkinson's diseaseCarl E Clarke, A Peter Moore
BMJ Clinical Evidence|May 21, 2009
Parkinson's diseaseCarl E Clarke, A Peter Moore
Neurology|April 14, 2004
Botulinum toxin A improves involuntary limb movements in Rasmussen syndromeDora A Lozsadi, Ian K Hart, A Peter Moore
Movement Disorders : Official Journal of the Movement Disorder Society|February 9, 2002
Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystoniaSusan H Fox, Mark Kellett, A Peter Moore, et al.
Pageof 2